On the 28th, Institut Pasteur Korea held a global workshop online under the theme of ‘Innovative strategies to respond to antibiotic resistance.’ This workshop was prepared to explore strategies for rapid antibiotic development and effective use of antibiotics with six global experts in basic and applied research, clinical practice, and international cooperation to respond to antibiotic resistance.
In particular, Professor Kevin Outerson of Boston University, founding director of CARB-X, announced a partnership strategy with Korean researchers and met with Ji Young-mi, director of Institut Pasteur Korea, to discuss cooperation between the two institutions. CARB-X is a global public-private partnership to eradicate antibiotic-resistant bacteria. It is supported by the US, UK, and German governments, the Wellcome Trust, and the Bill & Melinda Gates Foundation. It selects and funds excellent basic research in the fields of treatment, vaccines, and diagnostics for resistant bacterial infections. provides.
In addition, Soo-jin Jang, head of the Antibiotic Resistance Research Team at Institut Pasteur Korea, Chung-min Ryu, head of the Infectious Disease Research Center at the Korea Research Institute of Bioscience and Biotechnology, Young-rak Cho, Vice President of LegoChem Bioscience, and Professor Yu-hee Cho of Cha Medical School presented the latest antibiotic development strategies, technologies, and research status. In addition, Professor Yong Dong-eun, director of the Bacterial Resistance Research Institute at Yonsei University College of Medicine, shared the current status of the use of bacteriophages, the latest treatment method.
The World Health Organization (WHO) predicted that annual deaths due to antibiotic-resistant bacterial infections could increase from the current 700,000 to up to 10 million by 2050, and the U.S. Centers for Disease Control and Prevention (CDC) recently predicted an increase in antibiotic use due to COVID-19. presented an analysis that the threat of resistant bacteria has grown further due to the increased burden on the health and medical system.
Institut Pasteur Korea is accelerating the development of innovative antibiotics and global research cooperation based on ultra-high-speed, high-capacity screening technology that can identify excellent new drug candidates.
In particular, we developed a new antibiotic candidate effective against methicillin-resistant bacteria (MRSA), a major domestic and foreign resistant bacteria, and linked it to follow-up development through technology transfer. We also developed a candidate material that inhibits Pseudomonas aeruginosa, which is resistant to kappabenem, the most powerful antibiotic in existence. was derived and the mechanism was identified.
In addition, research is being conducted to analyze trends in resistant bacteria due to the increased use of antibiotics for the treatment of COVID-19.
In addition, we have been conducting collaborative research since 2018 with the Global Antibiotic Research and Development Partnership (GARDP), an international non-profit organization established by WHO and the Foundation for the Development of New Antibiotics for Neglected Diseases (DNDi) to develop new antibiotics. I am participating.
Director Ji Young-mi said, “The core of major strategies to respond to antibiotic resistance, such as ‘One Health,’ is global cooperation,” and added, “Through this workshop, we will discuss antibiotic development innovation strategies and international partnerships with domestic and foreign industry, academia, research, and medical experts. We discussed expansion plans in depth, and we will actively exchange and cooperate to accelerate research and development and strengthen our network.”
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asian Innovation Hub Pangyo Techno Valley 2022’ news